Due to the
rising prevalence of gastroesophageal reflux disease (GERD) and stomach and
intestinal ulcers, healthcare experts have taken a strong interest in their
treatment. GERD is a frequent health disease that can result in major medical
consequences as well as a significant financial outlay for diagnosis and
treatment. Heartburn and acid regurgitation are the two most common symptoms
associated with GERD. To reduce the effects of stomach acids or stop acid
production, over-the-counter antacids, proton pump inhibitors, and H-2 receptor
blockers are commonly utilised.
Ranitidine
is a histamine H2 antagonist that is used to treat gastroesophageal reflux
disease. It is available as an over-the-counter (OTC) and prescription medicine
(GERD). For up to 12 hours, ranitidine reduces stomach acid production. Erosive
esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome are all
treated with ranitidine. It can be administered either orally or intravenously.
Growing Research and Development
(R&D) on Ranitidine is expected to Boost Market Growth
Various
government and corporate research institutions are increasingly involved in
research and development studies to improve the efficacy of ranitidine and
analyse its potential to expand the scope of the ranitidine
market in the future.
Moreover, a
number of clinical trials are presently underway to determine and compare the
efficacy of ranitidine to other proton pump inhibitors like esomeprazole and
rabeprazole in reducing gastric acid in the stomach. The efficacy of ranitidine
is predicted to improve as a result of these research, and improved treatment
regimes for lowering excessive stomach acid production should be available in
the near future.
Rising Cases of Various Gastric
Ulcers and Digestive Diseases is expected to Increase Growth of the market
Because of
the high prevalence of gastroesophageal reflux disease (GERD), intestinal and
stomach ulcers, esophagitis, heartburn, and other digestive diseases caused by
an unhealthy lifestyle and changing dietary patterns, demand for ranitidine-based
medications is expected to rise in the near future. According to Florida
Hospital data from 2018, around 60 million adults in the United States suffer
from acid reflux symptoms on a monthly basis. Furthermore, according to the
source, an estimated 25 million of the 60 million adults suffer with acid
reflux symptoms on a daily basis. According to the same source, approximately
20% of those who suffer from acid reflux will acquire gastroesophageal reflux
disease (GERD) in the near future.
Comments
Post a Comment